Platelet-rich plasma (PRP)

The evidence base is narrow and indication-specific, and it does not support PRP as a longevity or healthspan protocol. There is genuine randomised human trial evidence for a small number of localised indications, principally androgenetic alopecia and some tendinopathies, with mixed and heterogeneous results driven by wide variation in preparation protocols (spin speed, platelet concentration, leukocyte content, activation method), which makes trials poorly comparable and results hard to generalise. For knee osteoarthritis, the most-studied longevity-adjacent indication, the larger and better-controlled trials have not shown benefit over saline injection. Critically, there is no evidence at all that PRP affects any systemic ageing outcome: no trial has shown an effect on biological age, mortality, healthspan, or any organ-system-wide measure. Its use as a "regenerative longevity" offering is a marketing extension of a local, cosmetic and musculoskeletal treatment, not a supported healthspan intervention, so it is graded commercial. Regulatory verification was incomplete and this is a material limitation of this profile: repeated live fetches of tga.gov.au (the TGA PRP/PRF/conditioned-serum guidance, the ARGB overview, and the autologous HCT PDF) all timed out across multiple attempts, so no TGA position is asserted here and auStatus is returned null rather than guessed. A credible secondary source (MIPS, the medical indemnity insurer) confirms the general shape of the Australian autologous human cell and tissue framework, including that products manufactured and used in an accredited hospital by a practitioner for their own patient sit outside TGA regulation, but that source does not mention PRP, so it cannot establish where PRP falls. For Singapore, HSA product-level status under the Cell, Tissue and Gene Therapy Product framework (in force since 1 March 2021, Class 1 versus Class 2 by degree of manipulation) could not be verified for PRP specifically. What was verified is a professional-practice restriction rather than a product approval, described in sgStatus. Offering confirmation is solid for Australia and absent for Singapore: Bespoke Longevity's own itemised treatment menu lists PRP explicitly across five indications with prices and membership bundles. PRP is near-ubiquitous in Singapore aesthetic practice, but no service page for any named Singapore longevity clinic stating PRP was opened, so Singapore is recorded as unconfirmed rather than absent.

What it is

Plain-language explainer

Categories

Common questions

What is Platelet-rich plasma (PRP)?

The evidence base is narrow and indication-specific, and it does not support PRP as a longevity or healthspan protocol. There is genuine randomised human trial evidence for a small number of localised indications, principally androgenetic alopecia and some tendinopathies, with mixed and heterogeneous results driven by wide variation in preparation protocols (spin speed, platelet concentration, leukocyte content, activation method), which makes trials poorly comparable and results hard to generalise. For knee osteoarthritis, the most-studied longevity-adjacent indication, the larger and better-controlled trials have not shown benefit over saline injection. Critically, there is no evidence at all that PRP affects any systemic ageing outcome: no trial has shown an effect on biological age, mortality, healthspan, or any organ-system-wide measure. Its use as a "regenerative longevity" offering is a marketing extension of a local, cosmetic and musculoskeletal treatment, not a supported healthspan intervention, so it is graded commercial. Regulatory verification was incomplete and this is a material limitation of this profile: repeated live fetches of tga.gov.au (the TGA PRP/PRF/conditioned-serum guidance, the ARGB overview, and the autologous HCT PDF) all timed out across multiple attempts, so no TGA position is asserted here and auStatus is returned null rather than guessed. A credible secondary source (MIPS, the medical indemnity insurer) confirms the general shape of the Australian autologous human cell and tissue framework, including that products manufactured and used in an accredited hospital by a practitioner for their own patient sit outside TGA regulation, but that source does not mention PRP, so it cannot establish where PRP falls. For Singapore, HSA product-level status under the Cell, Tissue and Gene Therapy Product framework (in force since 1 March 2021, Class 1 versus Class 2 by degree of manipulation) could not be verified for PRP specifically. What was verified is a professional-practice restriction rather than a product approval, described in sgStatus. Offering confirmation is solid for Australia and absent for Singapore: Bespoke Longevity's own itemised treatment menu lists PRP explicitly across five indications with prices and membership bundles. PRP is near-ubiquitous in Singapore aesthetic practice, but no service page for any named Singapore longevity clinic stating PRP was opened, so Singapore is recorded as unconfirmed rather than absent.

How strong is the evidence for Platelet-rich plasma (PRP)?

Commercial. It is offered and sold, which is a statement about availability, not about efficacy.

Is Platelet-rich plasma (PRP) approved in Singapore?

Health Sciences Authority position on record: Not verified at HSA product level, and returned with an important caveat. HSA's Cell, Tissue and Gene Therapy Product framework has applied since 1 March 2021, classifying products Class 1 or Class 2 by degree of manipulation and intended use, but no HSA determination specific to PRP was retrieved, so its product classification is unknown. Separately, at the practice level, PRP does not appear anywhere in Table 1 or Table 2 of the Singapore Medical Council's Guidelines on Aesthetic Practices for Doctors (2016 edition, in effect 1 August 2016), the tables that enumerate the aesthetic procedures doctors are permitted to perform. Paragraph 26 of that document states that, except within a formal and approved clinical trial, doctors are not to perform aesthetic procedures that are not listed unless they have been classified by the Aesthetic Practice Oversight Committee under Table 1 or Table 2. Paragraphs 23 and 24 also record that MOH discontinued the former List B category from 1 March 2015 after finding results largely equivocal. On its face this means aesthetic PRP (facial rejuvenation, hair) is a non-listed procedure in Singapore unless APOC has since classified it; whether APOC has done so, and whether the 2016 guidelines remain the current edition as at July 2026, was NOT verified and should be checked before publication. This restriction applies only where the primary aim is aesthetic; PRP used for musculoskeletal indications falls outside these guidelines and is not addressed here.. An evidence grade and a regulatory approval are different questions.

Is Platelet-rich plasma (PRP) approved in Australia?

variis has no Therapeutic Goods Administration position on file for Platelet-rich plasma (PRP). Absence of a recorded position is not approval.

Which clinics offer Platelet-rich plasma (PRP)?

1 clinic in the variis directory across Singapore and Australia has Platelet-rich plasma (PRP) on record. Each is listed on this page with its own sourced profile.

What else is Platelet-rich plasma (PRP) called?

Also known as PRP, autologous platelet-rich plasma, platelet concentrate injection, platelet-rich fibrin (PRF), vampire facial.